JNJ241206C220000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Why Is Johnson & Johnson (JNJ) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
The Analyst Landscape: 15 Takes On Johnson & Johnson
Press Release: Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Express News | B of A Securities Reinstates Neutral on Johnson & Johnson, Announces $166 Price Target
Johnson & Johnson Analyst Ratings
Johnson & Johnson's Carvykti Shows Promising Late-Stage Study Results for Multiple Myeloma
EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk
Express News | J&J - Carvykti® Demonstrated Significantly Higher Rates of Minimal Residual Disease Negativity Compared to Standard Therapies in Cartitude-4 Study
Johnson & Johnson Snaps Six Days of Losing Streak
GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex
GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care
GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse
GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma
GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care
GSK: Blenrep Combination Late-Stage Trial Reduced Risk of Death by 42% in Patients With Multiple Myeloma at or After First Relapse